The estimated Net Worth of Tyler Lipschultz is at least 2.23 百万$ dollars as of 1 January 2023. Mr. Lipschultz owns over 8,362 units of SeaSpine Corp stock worth over 1,284,990$ and over the last 14 years he sold SPNE stock worth over 0$. In addition, he makes 947,669$ as Senior Vice President、 Orthobiologics and Business Development at SeaSpine Corp.
Tyler has made over 5 trades of the SeaSpine Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 8,362 units of SPNE stock worth 79,773$ on 1 January 2023.
The largest trade he's ever made was exercising 31,687 units of SeaSpine Corp stock on 31 December 2019 worth over 302,294$. On average, Tyler trades about 4,608 units every 61 days since 2011. As of 1 January 2023 he still owns at least 134,695 units of SeaSpine Corp stock.
You can see the complete history of Mr. Lipschultz stock trades at the bottom of the page.
Tyler P. Lipschultz serves as Senior Vice President, Orthobiologics and Business Development of the Company. Mr. Lipschultz held positions of increasing responsibility at NuVasive, Inc., a publicly traded medical device company, most recently serving as its executive vice president, global operations and, prior to that, executive vice president, biologics. Prior to joining NuVasive, Mr. Lipschultz was a director at ProtoStar, a medical device incubator that formed Annulex, CVRx, and VERTx, which he co-founded. In 2002, VERTx merged with Spine Wave, where Mr. Lipschultz subsequently served in a variety of roles, including executive vice president and general manager of the mechanical business. Prior to ProtoStar, Mr. Lipschultz held the position of Equity Research Analyst at Piper Jaffray and served in various marketing/product management roles at Stryker, Smith & Nephew, and DePuy. Mr. Lipschultz received a B.A. in economics and business administration from Kalamazoo College and an M.B.A. from the executive program at Krannert School of Management at Purdue University.
As the Senior Vice President、 Orthobiologics and Business Development of SeaSpine Corp, the total compensation of Tyler Lipschultz at SeaSpine Corp is 947,669$. There are 3 executives at SeaSpine Corp getting paid more, with Keith Valentine having the highest compensation of 1,840,570$.
Tyler Lipschultz is 53, he's been the Senior Vice President、 Orthobiologics and Business Development of SeaSpine Corp since 2018. There are 7 older and 12 younger executives at SeaSpine Corp. The oldest executive at SeaSpine Holdings Corp is Keith Bradley, 75, who is the Independent Director.
Tyler's mailing address filed with the SEC is C/O SEASPINE HOLDINGS CORPORATION, 5770 ARMADA DRIVE, CARLSBAD, CA, 92008.
Over the last 9 years, insiders at SeaSpine Corp have traded over 2,659,931$ worth of SeaSpine Corp stock and bought 297,805 units worth 3,591,897$ . The most active insiders traders include Stuart Essig、Richard E Caruso、Keith Valentine. On average, SeaSpine Corp executives and independent directors trade stock every 39 days with the average trade being worth of 151,762$. The most recent stock trade was executed by John J. Winge on 1 January 2023, trading 4,868 units of SPNE stock currently worth 46,441$.
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide.
SeaSpine Corp executives and other stock owners filed with the SEC include: